This is a Phase III, multicenter, open-label clinical study designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab pro…

Von Willebrand Disease, Type 3

~Estimated

~$10 – $7,500

Hoffmann-La RocheNCT06998524

Phase 1

Emicizumab for Severe VON Willebrand Disease (VWD) and VWD/Hemophilia A

Von Willebrand Disease (VWD) is the most common inherited bleeding disorder affecting up to 0.1% of the population, is usually characterized by mucocutaneous b…

Von Willebrand Disease, Type 3Concomitant VWD and Hemophilia

~Estimated

~$10 – $7,500

Bleeding and Clotting Disorders Institute Peoria, IllinoisNCT05500807